

NCT ID	NCT04362839
Title	Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2020-04-27
Location	California, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Ipilimumab, Nivolumab, Regorafenib, Opdivo, Stivarga, Yervoy
Tags	MSS/ MMRp
NCT ID	NCT04332653
Title	NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2020-04-03
Location	Florida, United States Michigan, United States Missouri, United States North Carolina, United States Pennsylvania, United States Tennessee, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Completed
Drugs	NT-I7, Pembrolizumab
Tags	MSS/ MMRp
NCT ID	NCT04262687
Title	Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate
Phase	Phase 2
Date Added	2020-02-10
Location	France
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Bevacizumab, capecitabine, oxaliplatin, Pembrolizumab
Tags	MSS/ MMRp
NCT ID	NCT04185883
Title	Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Phase	Phase 1
Date Added	2019-12-04

Location	Arizona, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Maryland, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Belgium Canada Germany Italy Japan Netherlands South Korea Spain Taiwan United Kingdom
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	afatinib, AMG 404, Atezolizumab, carboplatin, pemetrexed, docetaxel, everolimus, FOLFIRI, FOLFOX, MVASI® (bevacizumab-awwb), palbociclib, panitumumab, Pembrolizumab, RMC-4630, Sotorasib, TNO155, Trametinib
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04130854
Title	INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer
Phase	Phase 2
Date Added	2019-10-18
Location	Arizona, United States North Carolina, United States Oregon, United States Texas, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and Radiation Therapy 5Gy x 5 days
Tags	MSS/ MMRp
NCT ID	NCT04117087
Title	Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer
Phase	Phase 1

Date Added	2019-10-07
Location	Maryland, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Ipilimumab, Nivolumab, Opdivo, Yervoy
Tags	MSS/ MMRp
NCT ID	NCT04110093
Title	Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
Phase	Phase 1/Phase 2
Date Added	2019-10-01
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Regorafenib and PD-1 inhibitor
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04111172
Title	A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
Phase	Phase 2
Date Added	2019-10-01
Location	Pennsylvania, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04111458
Title	A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
Phase	Phase 1
Date Added	2019-10-01
Location	Massachusetts, United States North Carolina, United States Tennessee, United States Texas, United States Germany Netherlands
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	BI 1701963, Trametinib
Tags	MSS/ MMRp
NCT ID	NCT04104776
Title	A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Phase	Phase 1
Date Added	2019-09-26

Location	Georgia, United States
	Illinois, United States
	Maryland, United States
	Massachusetts, United States
	Michigan, United States
	New Jersey, United States
	New York, United States
	Ohio, United States
	Pennsylvania, United States
	Texas, United States
	Virginia, United States
	Washington, United States
	France
	Italy
	Korea, Republic of
	Poland
	Spain
	United Kingdom
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	CPI-0209, CPI-0209
Tags	MSI-H/ MMRd, MSS/ MMRp